SIOX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SIOX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Sio Gene Therapies's revenue per share for the three months ended in Dec. 2022 was $0.00. Sio Gene Therapies's revenue per share for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Sio Gene Therapies's Revenue per Share or its related term are showing as below:
The historical data trend for Sio Gene Therapies's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sio Gene Therapies Annual Data | |||||||||||||||||
Trend | Mar15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | |||||||||
Revenue per Share | Get a 7-Day Free Trial | - | - | - | - | - |
Sio Gene Therapies Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Revenue per Share | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Sio Gene Therapies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sio Gene Therapies's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Sio Gene Therapies's Revenue Per Share for the fiscal year that ended in Mar. 2022 is calculated as
Revenue Per Share (A: Mar. 2022 ) | = | Revenue (A: Mar. 2022 ) | / | Shares Outstanding (Diluted Average) (A: Mar. 2022 ) |
= | 0 | / | 73.212 | |
= | 0.00 |
Sio Gene Therapies's Revenue Per Share for the quarter that ended in Dec. 2022 is calculated as
Revenue Per Share (Q: Dec. 2022 ) | = | Revenue (Q: Dec. 2022 ) | / | Shares Outstanding (Diluted Average) (Q: Dec. 2022 ) |
= | 0 | / | 73.975 | |
= | 0.00 |
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sio Gene Therapies (OTCPK:SIOX) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Sio Gene Therapies's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Parag V Meswani | officer: Chief Commercial Officer | 130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036 |
Pavan Cheruvu | officer: Chief Executive Officer | C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036 |
Atul Pande | director | C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
Kristiina Md Vuori | director | C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Eric Venker | director | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
David W. Nassif | officer: Principal Financial Officer | C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583 |
Senthil Vel Sundaram | director | NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453 |
Dexxon Holdings Ltd. | 10 percent owner | 1 DEXCEL STREET, OR AKIVA L3 30600000 |
Andrew Lo | 10 percent owner | C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142 |
Svf Investments (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET, LONDON X0 W1K3JP |
Patrick Machado | 10 percent owner | 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107 |
Qvt Associates Gp Llc | 10 percent owner | 1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036 |
Viking Global Performance Llc | 10 percent owner | 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
From GuruFocus
By Marketwired Marketwired • 02-04-2021
By Marketwired Marketwired • 08-12-2021
By GlobeNewswire GlobeNewswire • 10-21-2021
By Marketwired Marketwired • 10-04-2021
By Marketwired Marketwired • 05-13-2021
By Marketwired Marketwired • 11-01-2021
By GuruFocusNews GuruFocusNews • 02-02-2022
By Value_Insider Value_Insider • 12-14-2022
By Marketwired Marketwired • 09-23-2021
By Marketwired Marketwired • 02-16-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.